New Long COVID studies demonstrate danger of breakthrough cases

Two new studies on Long COVID, published this week, provide an important reminder of the continued dangers this condition poses to people infected with the coronavirus—even after vaccination. Neither study provides wholly new information, but both are more comprehensive than many other U.S. papers on this condition as they’re based on large databases of electronic health records.

Read More

We need more data on who’s getting Paxlovid

Last week, I shared a new page from the Department of Health and Human Services (HHS), reporting statistics on COVID-19 therapeutic distribution in the U.S. The new dataset is a helpful step, but it falls far short of the information we actually need to examine who has access to COVID-19 treatments (particularly Paxlovid) and address potential health equity issues.

Read More

National numbers, May 29

America’s largely-ignored BA.2 surge continues: the U.S. reported over 100,000 new cases a day last week, while an average of 3,600 new COVID-19 patients were admitted to hospitals each day. Both of these metrics rose about 8% from the week prior.

Read More

Interpreting limited data in our undercounted surge

There’s no sugarcoating it: we are in an extremely confusing and frustrating phase of the pandemic. We see the rising (yet undercounted) case numbers, we hear from friends and family members who have recently tested positive. And yet the CDC’s official COVID-19 guidance is still based on a mostly-green map, while local leaders refuse to reinstate mask mandates or other safety measures.

Read More

National numbers, May 22

The Omicron BA.2 surge continues in the U.S., with a 19% increase in officially-reported COVID-19 cases in the past week to over 100,000 new cases a day. Of course, the official case numbers severely underestimate true infections, as PCR testing sites close and more people use rapid tests; actual case counts may be five or more times higher.

Read More